Check Out How CarboHyde Cyclodextrin Polymers Worked in Delivery!
Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months. Emerging therapeutic approaches target the MAPK/ERK signalling pathway using MEK inhibitors such as trametinib and selumetinib. However, clinical progress faces obstacles including inadequate blood-brain barrier penetration and dose-limiting toxicity concerns. Researchers Noemi Bognanni, Graziella Vecchio, and […]
